Search results
Results From The WOW.Com Content Network
Since 2008, Pfizer has engaged in extensive direct-to-consumer advertising campaigns to promote its branded product Lyrica for fibromyalgia and diabetic nerve pain indications. In January 2016, the company spent a record amount, $24.6 million for a single drug on TV ads, reaching global revenues of $14 billion, more than half in the United States.
Pfizer: Off-label promotion of Bextra, Geodon, Zyvox and Lyrica, September 2009. In what was the largest pharmaceutical settlement in U.S. history at the time, Pfizer reached a $2.3 billion settlement with the Department of Justice to resolve criminal charges and civil claims under the False Claims Act.
Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures NEW YORK--(BUSINESS ...
4-Methylpregabalin. 4-Methylpregabalin is a drug developed by Pfizer and related to pregabalin, which similarly acts as an analgesic with effectiveness against difficult to treat "atypical" pain syndromes such as neuropathic pain. The effectiveness of pregabalin and its older relative gabapentin against pain syndromes of this kind (which tend ...
As revenue at Pfizer continues to decline, some relief may come in the form of a new indication for Lyrica, one of the company's top-selling drugs, to treat restless legs syndrome, or RLS. Lyrica ...
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Even after receiving samples, sample recipients remain disproportionately burdened by prescription costs. [7] It is argued that a benefit to free samples is the "try it before you buy it" approach. Free samples give immediate access to the medication and the patient can begin treatment right away.
Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release As Treatment For Patients With Fibromyalgia NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYS: PFE) today ...